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Papers
The clinicopathological features and importance
of p53, Rb, and mdm2 expression in
phaeochromocytomas and paragangliomas
K Y Lam, C Y Lo, N M S Wat, J M Luk, K S L Lam
Abstract
Aims—Phaeochromocytomas and para-
gangliomas are uncommon. The aims of
this study were to analyse the characteris-
tics and the possible roles of p53, Rb, and
mdm2 alterations in these tumours.
Methods—The clinicopathological fea-
tures of 65 patients (31 men, 34 women)
with phaeochromocytomas or paragang-
liomas were analysed. The tumours were
studied for the expression of p53, Rb, and
mdm2 by immunohistochemical methods.
Results—Thirty nine of the patients had
phaeochromocytomas and 26 had para-
gangliomas. Bilateral tumours were noted
in eight of the patients and malignant
tumours were seen in 13. Paragangliomas
were often small, non-functional, and pre-
sented incidentally, whereas phaeochro-
mocytomas were usually large, functional,
and symptomatic. p53 overexpression,
loss of Rb expression, and mdm2 overex-
pression were seen in four, 43, and 37 of
the patients, respectively. Three of the
four patients with p53 overexpression had
bilateral tumours. Loss of Rb expression
was often found in phaeochromocytomas,
whereas mdm2 overexpression was more
frequently seen in paragangliomas. The 10
year survival rate of patients with malig-
nant tumours was 45%. Two patients died
of tumour metastases more than 10 years
after resection of the primary tumours.
Conclusions—Phaeochromocytomas and
paragangliomas had distinctive clinical
features and genetic alterations. The
prognosis of patients with these tumours
was related to the malignant potential. p53
overexpression,more common in bilateral
phaeochromocytomas and paraganglio-
mas, could be a marker for this tumour
subgroup.
(J Clin Pathol 2001;54:443–448)
Keywords: phaeochromocytoma; paraganglioma; p53
The products of the p53, retinoblastoma (Rb),
and mouse double minute 2 (mdm2) genes are
important modulators of the cell cycle.1–3 The
p53 and Rb genes are tumour suppressor
genes, whereas the mdm2 gene is a proto-
oncogene, which produces a protein that
inhibits the function of the p53 and Rb
proteins.1–3 Wild-type p53 protein is labile,
whereas mutant forms have longer half lives
and can be detected by immunohistochemistry.
In contrast, the Rb protein can be detected in
non-neoplastic tissue, and mutations of the Rb
gene could result in the loss of Rb staining.
Lastly, amplification of the mdm2 gene may
lead to mdm2 protein overexpression.
The role of p53 alterations in phaeo-
chromocytomas/paragangliomas has been in-
vestigated in several studies.4–14 However, to the
best of our knowledge, the importance of Rb
and mdm2 aberrations in human
phaeochromocytomas/paragangliomas has
never been studied. In our study, we analysed
the clinicopathological features of patients with
phaeochromocytomas and paragangliomas.
The possible roles of alterations in the p53, Rb,
and mdm2 genes and their interaction in these
tumours were also studied by means of immu-
nohistochemistry. Although the immunohisto-
chemical analysis of these cell cycle proteins
does not necessarily reflect genetic changes, it
allows genetic alterations to be localised and
correlated with other clinicopathological pa-
rameters.
Materials and methods
DATA COLLECTION
The patients who were chosen for our study
had phaeochromocytomas or paragangliomas
confirmed by histological examination during a
25 year study period (1973–97) at Queen Mary
Hospital. The age, sex, clinical presentation,
urinary catecholamine values, and survival data
of these patients were taken from the clinical
records. Macroscopically, the location and size
(maximum length) of the tumours were
recorded. The tumours were categorised as
either benign or malignant. Malignant
phaeochromocytomas/paragangliomas were
defined as tumours with unequivocal evidence
of metastatic disease(s).
PATHOLOGICAL REVIEW AND SELECTION OF
TISSUES
The histological sections of the tumours were
reviewed. The diagnoses were confirmed by
positivity to the neuroendocrine markers
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(neurone specific enolase, chromogrannin, and
synaptophysin). Electron microscopic exam-
ination was performed to detect the neuro-
secretory granules if the diagnosis was uncer-
tain. Representative paraYn wax blocks from
the tumours were chosen for immunohisto-
chemical studies.
IMMUNOSTAINING
The immunohistochemical study was con-
ducted on 5 µm thick paraYn wax sections
using the avidin–biotin–peroxidase complex
method. The antibodies against p53 (micro-
wave pretreated; NCL-p53-DO7 at a dilution
of 1/50), Rb (microwave pretreated; NCL-RB1
at a dilution of 1/50), and mdm2 (trypsin pre-
treated; NCL-MDM2 at a dilution of 1/50)
were from Novocastra Laboratories Ltd (New-
castle upon Tyne, UK). ParaYn wax blocks of
oesophageal squamous cell carcinoma (known
to be strongly positive for the p53 and Rb pro-
teins) and breast carcinoma (known to be
strongly positive for mdm2) were used as posi-
tive controls.4–7 Brown nuclear staining was
regarded as a positive signal, whereas cytoplas-
mic staining (non-specific background stain-
ing) was considered to be negative. In addition,
tumours with less than 5% of tumour cells with
a positive signal were defined as negative.
STATISTICAL ANALYSIS
Statistical analysis was performed using the
Student’s t test (continuous variables), with
Yates correction and ÷2/Fisher exact test
(categorical variables). The actuarial survival
rate of the patients was measured from the date
of resection of these tumours to the date of
death or of the last follow up. Survival was cal-
culated using the Kaplan–Meier method,
whereas the impact of survival by various
factors was examined by means of the log rank
test.
Results
Sixty five patients (31 men, 34 women) with
phaeochromocytomas/paragangliomas were
found (62 Chinese, two white, and one
Indian). The clinicopathological features of
patients are summarised in table 1 and some of
the cases had been described previously.15–17
CLINICOPATHOLOGICAL FEATURES
The mean age of the patients was 43 (range,
2–85). Thirty nine had phaeochromocytomas
and 26 had paragangliomas. Approximately
half (33) of the patients had functional
tumours (with raised urinary catecholamine
values) and 46 had been diagnosed correctly
before pathological examination. Thirty one of
the patients with phaeochromocytomas and
two of the patients with paragangliomas had
functional tumours. Paragangliomas studied
comprised: carotid body paragangliomas (12),
paragangliomas from the sympathetic trunk
(four in the retroperitoneum and two in the
bladder), middle ear (five), jaw (two), and base
of the skull (one).
Thirty six of the patients had lesions on the
right side of body, 21 had left sided tumours,
and eight had bilateral tumours. The last group
comprised four patients suVering from bilateral
phaeochromocytomas and four with bilateral
carotid body tumours. Thus, we analysed a
total of 73 phaeochromocytomas and paragan-
gliomas. On gross examination, the tumours
usually appeared light brown in colour. The
mean diameter of these tumours was 5 cm
(range, 0.2–17). Malignancy was noted in 13 of
the patients.
Phaeochromocytomas were often functional,
usually leading to a correct diagnosis before
histological examinations were conducted,
whereas paragangliomas were normally non-
functional tumours and detected incidentally
(p = 0.0001 and p = 0.025, respectively). The
mean diameter of the phaeochromocytomas
was significantly larger than paragangliomas (6
v 3.5 cm; p = 0.002). Phaeochromocytomas
were detected more often on the right side
(right to left ratio, 1.9 : 1), whereas paragang-
liomas did not seem to have a predilection for
either side (right to left ratio, 1.1 : 1).
Nevertheless, the diVerence between phaeo-
chromocytomas and paragangliomas with re-
spect to side predilection was not significant
(p = 0.32). Bilateral paragangliomas were lim-
ited to the location at carotid bodies. One third
(four of 12) of the patients with carotid body
tumours suVered from bilateral growth
whereas no patients with other paragangliomas
had bilateral lesions (p = 0.033). There was no
significant diVerence between the phaeochro-
mocytomas and paragangliomas with respect
to the age (p = 0.45; Student’s t test) or sex
(p = 1) of the patients or malignant potential of
the tumours (p = 1).
p53 EXPRESSION
Four patients had p53 overexpression: three
with phaeochromocytomas and one with ca-
rotid body tumours. Bilateral phaeochromocy-
tomas were found in two of the three patients
with p53 overexpression. Among them, one
had multiple endocrine neoplasia type 2
(MEN2) and another died of bilateral phaeo-
chromocytomas with metastases (no necropsy
or genetic screening was performed to verify
the presence of MEN2). The third patient with
a p53 positive phaeochromocytoma was a 2
year old boy (the youngest patient in our
series). He was lost to follow up. The patient
with p53 positive bilateral carotid body tu-
mours also had familial tumours and her
brother also suVered from bilateral carotid
body paragangliomas. The diVerence in p53
overexpression in the patients with and without
bilateral tumours was significant (p = 0.003).
The patients with p53 positive tumours did not
diVer significantly from those with p53 nega-
tive ones with respect to age at presentation
(p = 0.16), sex (p = 1), clinical presentation
(p = 1), and functional status (p = 0.61). Fur-
thermore, there was no diVerence between p53
positive and p53 negative tumours in relation
to their size (p = 0.36), location (adrenal
medulla v extra-adrenal; p = 0.64), and malig-
nant potential (p = 1).
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Rb EXPRESSION
Twenty two of the patients showed Rb staining.
Loss of Rb expression was noted in 35 of the
39 patients with phaeochromocytomas and
eight of the 18 patients with paragangliomas.
Therefore, loss of Rb was more frequently
detected in phaeochromocytomas than in
paragangliomas (p = 0.0001). In addition, Rb
positive tumours were often non-functional
(p = 0.0001) and of smaller size (p = 0.001).
There was no significant diVerence between
patients with Rb positive and Rb negative
tumours with respect to age at presentation
(p = 0.58), sex (p = 1), clinical presentation
(p = 0.78), bilaterality (p = 1), or malignant
potential (p = 0.5).
Table 1 Clinicopathological features of patients with phaeochromocytoma or paraganglioma
Case Sex/age Side Site
Size
(cm)
Malignant/
Benign
Expression
Func Dx Remarksp53 Rb mdm2
1 F/21 Right Adrenal 3.0 Benign 0 + 0 Yes Yes –
2 M/57 Left Adrenal 9.0 Malignant 0 0 0 Yes Yes DOD after 8 years
3 M/33 Right Adrenal 3.5 Benign 0 0 0 Yes Yes –
4 F/30 Left Adrenal 8.0 Benign 0 0 + Yes Yes –
5 M/2 Right Adrenal 3.0 Benign + 0 0 Yes No –
6 M/52 Right Adrenal 9.0 Benign 0 0 + Yes Yes –
7 M/22 Left Adrenal 5.0 Benign 0 0 + Yes Yes –
8 M/36 Right Adrenal 5.0 Malignant 0 0 0 Yes Yes DOD after 16 years
9 M/63 Right Adrenal 8.0 Benign 0 0 + Yes Yes –
10 F/35 Left Adrenal 5.0 Malignant 0 0 0 Yes Yes AWD after 17 years
11 F/32 Right Adrenal 8.5 Benign 0 0 + Yes Yes Alive after 1 year
12 F/22 Right Adrenal 8.0 Benign 0 + + Yes Yes –
13 F/18 Right Adrenal 7.5 Benign 0 0 0 Yes Yes Alive after 4.3 years
14 M/26 Right Adrenal 5.0 Benign 0 0 + No No –
15 F/46 Right Adrenal 8.0 Malignant 0 0 0 No Yes AWD after 3.2 years
16 F/40 Right Adrenal 5.0 Benign 0 0 0 Yes Yes Alive after 5 months
17 M/59 Right Adrenal 5.0 Benign 0 0 + Yes Yes Alive after 11.6 years
18 F/62 Right Adrenal 9.0 Benign 0 0 0 Yes Yes Alive after 1.2 years
19 M/53 Right Adrenal 12.0 Benign 0 0 0 Yes Yes Alive after 1.3 years
20 M/38 Right Adrenal 3.0 Benign 0 0 0 Yes Yes Alive after 12 years;
Left Adrenal 1.0 MEN2
21 F/32 Left Adrenal 3.0 Benign 0 0 0 Yes Yes Alive after 10.6 years
22 F/34 Right Adrenal 5.0 Benign 0 0 0 Yes Yes Alive after 9.1 years
23 F/58 Right Adrenal 5.0 Benign 0 0 0 Yes Yes Alive after 7.3 years
24 M/54 Left Adrenal 4.0 Benign 0 0 0 Yes Yes Alive after 6.1 years
25 M/65 Right Adrenal 9.5 Benign 0 0 0 Yes Yes Alive after 4.6 years
26 M/42 Left Adrenal 6.0 Malignant 0 0 + Yes Yes Alive after 12.4 years
27 M/63 Right Adrenal 8.0 Malignant + + 0 Yes Yes DOD after 2 years
Left Adrenal 4.5
28 M/48 Left Adrenal 6.8 Benign 0 0 + Yes Yes Alive after 2.8 years
29 F/62 Left Adrenal 11.5 Malignant 0 0 0 No No Died shortly after OT
30 F/51 Right Adrenal 2.5 Benign 0 0 + No Yes Alive after 3.8 years;
Left Adrenal 1.7 MEN2
31 F/62 Right Adrenal 6.0 Benign 0 0 + Yes Yes Alive after 3.8 years
32 F/56 Right Adrenal 2.0 Benign 0 0 0 Yes Yes Alive after 1 year
33 F/73 Right Adrenal 8.0 Benign 0 0 + Yes Yes Alive after 11 months
34 F/33 Right Adrenal 2.0 Benign 0 0 + Yes Yes Alive after 8 months
35 F/40 Right Adrenal 11.0 Benign + + 0 Yes Yes Alive after 7 months;
Left Adrenal 4.5 MEN2
36 M/42 Left Adrenal 1.0 Benign 0 0 + No No Incidental PM finding
37 M/71 Right Adrenal 13.0 Malignant 0 0 + No No Incidental PM finding
38 M/50 Right Adrenal 5.0 Benign 0 0 + No No Incidental PM finding
39 F/47 Left Adrenal 8.0 Benign 0 0 0 No No Incidental PM finding
40 M/50 Right Carotid body 17.0 Malignant 0 0 0 No No Incidental PM finding
41 M/40 Right Jaw 2.5 Benign 0 + + No No –
42 F/68 Right Retroperitoneum 3.5 Benign 0 0 + No No Died shortly after OT
43 F/39 Left Middle ear 0.5 Benign 0 0 0 No Yes –
44 F/50 Right Middle ear 0.5 Benign 0 + + No Yes –
45 M/63 Left Jaw 0.5 Benign 0 + + No No –
46 M/25 Right Carotid body 3.0 Benign 0 + + No No –
47 M/22 Left Carotid body 3.0 Malignant 0 + 0 No No DOD after 13 years
48 F/26 Right Carotid body 4.0 Benign 0 + + No Yes Alive after 16.4 years
Left Carotid body 2.5
49 F/39 Right Middle ear 0.7 Benign 0 + + No Yes Alive after 12.3 years
50 F/60 Right Middle ear 1.0 Benign 0 + + No Yes –
51 F/23 Right Retroperitoneum 10.0 Malignant 0 0 + Yes Yes DOD after 6.5 years
52 F/28 Left Bladder 5.0 Malignant 0 0 + Yes No AWD after 12.4 years
53 M/19 Right Carotid body 3.5 Benign 0 0 + No No Alive after 11.3 years
54 M/53 Right Bladder 3.0 Benign 0 0 + No No Alive after 10 years; with rectal carcinoid
55 F/21 Right Carotid body 5.0 Benign + 0 + No Yes Brother had carotid body tumour;
Left Carotid body 2.0 alive after 8.8 years
56 M/34 Right Carotid body 4.0 Benign 0 + + No Yes Sister had carotid body tumour;
Left Carotid body 2.0 alive after 8.3 years
57 M/35 Left Base of skull 1.0 Benign 0 + + No No Alive after 6 years
58 F/28 Left Carotid body 3.0 Benign 0 + + No Yes Alive after 5.2 years
59 M/31 Left Carotid body 2.5 Benign 0 + + No Yes Alive after 5 years
60 F/30 Left Carotid body 4.5 Benign 0 + + No Yes Alive after 4 years
Right Carotid body 4.0
61 F/85 Left Retroperitoneum 0.6 Benign 0 + + No No Alive after 1.8 years
62 F/68 Left Middle ear 0.2 Benign 0 + + No Yes Alive after 2.1 years
63 M/36 Left Carotid body 3.5 Malignant 0 + 0 No Yes Alive after 1.7 years
64 M/59 Right Retroperiotneum 7.0 Benign 0 + 0 No No Alive after 1.3 years
65 F/33 Right Carotid body 3.0 Benign 0 + 0 No Yes Alive after 9 years
Expression: +, positive; 0, negative.
M, male; F, female; Func, functional tumour; Dx, clinical diagnostic; DOD, died of disease; AWD, alive with disease; PM, postmortem; OT, operation.
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mdm2 EXPRESSION
Thirty seven of the patients had mdm2 nuclear
staining. Mdm2 staining was found in 20 of the
26 patients with paragangliomas and 17 of the
39 patients with phaeochromocytomas. Thus,
the incidence of mdm2 staining was signifi-
cantly higher in paragangliomas than in phaeo-
chromocytomas (p = 0.011). The staining was
also detected frequently in non-functional
tumours (p = 0.024) and those of a smaller size
(p = 0.038). However, the patients with mdm2
positive tumours did not diVer from those with
mdm2 negative tumours with respect to age at
presentation (p = 0.85), sex (p = 1), or clinical
presentation (p = 0.28). There was no signifi-
cant diVerence between the two groups of
tumours in terms of the malignant potential
(p = 0.058) and the occurrence of bilateral
tumours (p = 1). Overall, there was no signifi-
cant correlation between p53, Rb, and mdm2
staining in the tumours studied.
SURVIVAL ANALYSIS
Survival data were available for 50 of the 65
patients. Five patients had tumours detected at
necropsy and two patients died shortly after
surgery. The median follow up of the remain-
ing 43 patients was 5.2 years. The survival rate
was not related to the patients’ sex (p = 0.12),
clinical presentation (p = 0.86), functional sta-
tus (p = 0.28), or tumour location (p = 0.75).
However, survival was related to the malignant
potential of the tumour (p = 0.01) (fig 1A).
Five patients with benign tumours were
detected at necropsy, whereas other patients
with benign tumours survived and had no
recurrence of disease during the follow up
period (median follow up, 4.6 years; range, 5
months to over 16 years). In comparison, only
45% of patients with malignant tumours
survived for 10 years. Although death in
patients with malignant tumours occurred
mainly within 10 years after the resection of the
primary tumour, two patients lived for more
than 10 years before dying of tumour related
diseases (one with malignant phaeochromocy-
toma and the other with malignant carotid
body tumour died of distant metastases 13 and
16 years, respectively, after surgery). The
survival rate of the patients with
phaeochromocytomas/paragangliomas ap-
peared to be higher in the patients with p53
negative tumours than those with p53 overex-
pression (p = 0.04), even though the number
of patients involved was quite small. However,
survival was not related to either Rb expression
(p = 0.8) or mdm2 expression (p = 0.26) (fig
1B–D).
Figure 1 Overall survival curves of patients with phaeochromocytomas/paragangliomas. (A) Benign versus malignant
tumours, p = 0.0001; (B) p53 overexpression (positive versus negative), p = 0.04; (C) Rb expression (positive versus
negative), p = 0.80; mdm2 overexpression (positive versus negative), p = 0.26.
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Discussion
The reported incidence of malignancy in
phaeochromocytomas/paragangliomas varies
among diVerent series.18 The variations may be
related to diVerences in the length of the follow
up period and the proportions of adrenal and
extra-adrenal tumours in the series. The
traditional figure of 10% is close to the average
of most studies.15 Paragangliomas have a
slightly higher rate of malignancy, from 14% to
50%.16 In our series, which contained a large
number of patients (predominately Chinese),
and with longterm follow up in many cases, the
rate of malignancy was found to be 20%. This
rate was similar both for phaeochromocytomas
and paragangliomas. The only criterion that
determined the prognosis of the patients with
phaeochromocytomas/paragangliomas was the
biological aggressiveness of the disease. Pa-
tients with benign tumours had longer term
survival, whereas the 10 year survival rate of
patients with malignant tumours was only
45%. Some patients with malignant tumours
died of metastatic tumours more than 10 years
after the resection of their primary tumours.
p53 alterations in phaeochromocytomas and
paragangliomas have been studied in a few
series (table 2).4–14 The number of patients
investigated in these series was usually small
(range, one to 36). In many of these studies, no
p53 aberration was found. On the contrary, Lin
et al in Taiwan and Yoshimoto et al in Japan and
China detected p53 mutations in phaeochro-
mocytomas.7 14 However, the mutation patterns
identified in these two studies were diVerent.
Both geographical and ethnic factors may have
aVected the mutational spectrum of p53 in dif-
ferent populations. Our investigation, which
studied a larger number of patients than the
other studies, showed the presence of p53
overexpression in four of the 65 phaeochromo-
cytomas and paragangliomas (including three
patients with phaeochromocytomas and one
with paraganglioma). Apart from our case, the
other p53 positive paragangliomas reviewed in
the English literature include a sporadic
paraganglioma reported by Dahia et al and a
lung paraganglioma, which occurred after
radiation exposure, described by Hagemeyer et
al.8 9
Hereditary factors have been reported in
phaeochromocytomas and paragangliomas.
Phaeochromocytoma can occur in the setting
of MEN2, an autosomal dominant disease of
disordered development and tumour forma-
tion that principally aVects thyroid C cells, the
adrenal medulla, and the parathyroids. Muta-
tions in the RET proto-oncogene, located on
chromosome 10, have been related to the
MEN2 syndrome. The gene encodes a recep-
tor tyrosine kinase expressed in tissues derived
from the neural crest. Familial paragangliomas
have been reported and were also noted in our
study. Recently, germ line mutations in SDHD,
a mitochondrial complex II gene, were found
to be responsible for this syndrome.19 Other
genetic alterations may be important in the
pathogenesis of phaeochromocytomas and
paragangliomas.
Bilateral phaeochromocytomas were often
noted in the patients with MEN2. Lin et al
found that p53 positive patients had either mul-
tiple or malignant phaeochromocytomas.7 In
agreement with this finding, we noted that the
p53 positive tumours were found in the patients
with bilateral tumours. The p53 positive
tumours occurred not only in a patient with
bilateral phaeochromocytomas (in MEN2) but
also in a patient with bilateral carotid body
tumours. Thus, p53 overexpression might play
a role in the pathogenesis of multiple phaeo-
chromocytomas and paragangliomas. It could
act as a marker for this subtype of tumour and
might be associated with poor prognosis.
Although paragangliomas and phaeochro-
mocytomas had identical histological features,
we found that they were diVerent in terms of
their clinical and genetic attributes. Clinically,
paragangliomas were often small, non-
functional, presented as incidental findings,
and did not show the side predilection seen in
phaeochromocytomas. In the patients with
paragangliomas, the carotid body was the only
location with bilateral tumours.
Our study represents the first examination of
phaeochromocytomas/paragangliomas for al-
terations in the Rb and mdm2 genes. The high
overall rate of loss of Rb staining (43 of 65) and
mdm2 expression (37 of 65) emphasised their
importance in the development of these
tumours. Loss of Rb staining was seen more
Table 2 Summary of studies concerning p53 alterations in phaeochromocytomas/paragangliomas
1st author/year/location
Analysis by
RemarksImmunohistochemistry LOH PCR-SSCP (exons studied)
Khosia/1991/USA – 7/29 – 17% are familial cases
Yana/1992/Japan – – – 0/30, exons 4–9 analysed by RNase protection analysis. Includes 10
hereditary cases
Yoshimoto/1993/Japan – 0/1 0/1 (exons 5–10) F/18 with MEN2B
Lin/1994/Taiwan 5/6 – 5/6 (exons 2–11) 2 male and 4 female patients
Hagemeyer/1994/Russia 1/1 – – Lung paraganglioma after exposure to atomic reactor accident
Dahia/1995/Brazil 1/25 – 0/25 (exons 4–8) 16% were malignant tumours; 4 were paragangliomas; 3 cases were familial;
the positive case was a benign, sporadic paraganglioma
Wang/1995/UK 0/36 – – Includes 24 phaeochromocytomas and 9 paragangliomas
Ballantine/1996/Australia – – 0/3 (exons 4–9)
Reincke/1996/USA 0/6 0/2 0/6 (exon 4) 2 male and 4 female patients
Herfarth/1997/USA 0/19 0/22 0/20 (exons 4–9) Includes 14 MEN2 and 1 von Hippel-Lindau disease
Yoshimoto/1998/Japan 3/4* – 6/33 (Exons 4–9) 21 Japanese and 12 Chinese patients (17 male, 16 female); positive cases
were either with multiple tumours or malignant tumours
Lam/1999/Hong Kong 4/65 – –
*Only cases positive for SSCP were analysed by immunohistochemistry.
LOH, loss of heterozygosity; MEN, multiple endocrine neoplasia; PCR-SCCP, polymerase chain reaction-single strand conformation polymorphism.
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often in phaeochromocytomas (35 of the 39
patients), whereas the presence of mdm2
expression was seen more frequently in para-
gangliomas (noted in 20 of the 26 patients).
This implies that the tumour suppressor Rb
and the oncoprotein mdm2 play diVerent roles
in the pathogenesis of phaeochromocytomas
and paragangliomas. Nevertheless, the altera-
tions in expression of these proteins did not
seem to aVect the biological aggressiveness and
survival of the patients with these tumours.
Mdm2 has recently been shown to interact
with tumour suppressor gene products (p53
and Rb) and inhibit their function.3 In our
study, no significant relation was found be-
tween the alterations of mdm2, p53, and Rb.
Recently, it has been noted that mdm2 might
function diVerently in p53 dependent and p53
independent pathways to regulate cellular pro-
liferation.4 In the former pathway, loss of p53
leads to a lack of mdm2 and thus to p53 protein
accumulation, and vice versa. In our patients,
mdm2 staining occurred in tumours with and
without p53 overexpression. Many patients
with paragangliomas had mdm2 expression but
no p53 protein overexpression. In addition, the
propensity of Rb and p53 alterations to occur
together in samples from the same patient was
noted previously in some tumours.20 In our
study, Rb and p53 alterations in phaeochromo-
cytomas and paragangliomas usually occurred
in the absence of each other.
Phaeochromocytomas and paragangliomas
have distinctive clinical features and genetic
alterations. They should not be treated as a
single entity although they have identical histo-
logical features. The expression profile of Rb
and mdm2 might help distinguish the two
lesions in some cases. In addition, the expres-
sion of p53 could be used as a marker for
familial phaeochromocytomas and paragang-
liomas, and might be useful in assessing the
prognosis of these patients.
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